| Tafasitamab studied in …STUDIED_INderived50 of 50show fewer |
|---|
| → studied in | NCT06029309Phase 1/Phase 2 · recruiting Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma · 50 trials list this drug (32 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615636Phase 2 · recruiting A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL · 50 trials list this drug (32 active) | — | — | B-Cell Malignant Neoplasm,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · 50 trials list this drug (32 active) | — | — | Classic Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · 50 trials list this drug (32 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680052Phase 3 · active not recruiting A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. · 50 trials list this drug (32 active) | — | — | Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502872Phase 2 · not yet recruiting TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma · 50 trials list this drug (32 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792825Phase 2 · recruiting HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · 50 trials list this drug (32 active) | — | — | Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma,Gray-Zone Lymphoma,Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07709624active not recruiting Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05351593Phase 1/Phase 2 · recruiting Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma · 50 trials list this drug (32 active) | — | — | Central Nervous System Lymphoma,Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04161248early Phase 1 · active not recruiting Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma · 50 trials list this drug (32 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974216Phase 2 · active not recruiting Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661007Phase 1/Phase 2 · active not recruiting To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) · 50 trials list this drug (32 active) | — | — | Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07585747Phase 2 · not yet recruiting A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide · 50 trials list this drug (32 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07582159Phase 2 · not yet recruiting Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 50 trials list this drug (32 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05453500Phase 2 · active not recruiting Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia · 50 trials list this drug (32 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05718869Phase 2 · active not recruiting Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study · 50 trials list this drug (32 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04978584Phase 2 · active not recruiting Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429268Phase 3 · active not recruiting Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981795completed realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030699Phase 2 · withdrawn A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma · 50 trials list this drug (32 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04646395Phase 2 · active not recruiting Study of Acalabrutinib and Tafasitamab in MZL Patients · 50 trials list this drug (32 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06760156Phase 2 · recruiting Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym · 50 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04824092Phase 3 · active not recruiting Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03930953Phase 1/Phase 2 · active not recruiting A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) · 50 trials list this drug (32 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05366218Phase 1/Phase 2 · recruiting Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia · 50 trials list this drug (32 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04809467Phase 1/Phase 2 · terminated A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) · 50 trials list this drug (32 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05222555Phase 1/Phase 2 · active not recruiting Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02005289Phase 2 · completed Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL · 50 trials list this drug (32 active) | — | — | Chronic Lymphocytic Leukemia,Prolymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465433Phase 2 · recruiting Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab · 50 trials list this drug (32 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05943496Phase 1 · recruiting Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma · 50 trials list this drug (32 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · 50 trials list this drug (32 active) | — | — | Transformed Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04607772Phase 1/Phase 2 · withdrawn Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) · 50 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05626322Phase 1/Phase 2 · terminated Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583071Phase 2 · recruiting Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL · 50 trials list this drug (32 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02763319Phase 2/Phase 3 · completed A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05788289Phase 2 · terminated A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma · 50 trials list this drug (32 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05910801Phase 2 · recruiting Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · 50 trials list this drug (32 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04134936Phase 1 · completed Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06521255Phase 3 · recruiting Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05328102Phase 2 · terminated Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) · 50 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01685008Phase 2 · completed Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) · 50 trials list this drug (32 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02399085Phase 2 · completed Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05205252Phase 1/Phase 2 · withdrawn A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · 50 trials list this drug (32 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05883709unknown A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL · 50 trials list this drug (32 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02639910Phase 2 · completed Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi · 50 trials list this drug (32 active) | — | — | Leukemia,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04882163Phase 1/Phase 2 · withdrawn Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma · 50 trials list this drug (32 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01685021Phase 2 · terminated Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) · 50 trials list this drug (32 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01161511Phase 1 · completed Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia · 50 trials list this drug (32 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |